Prelude Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
So welcome, everyone. Welcome, good afternoon to the JMP Healthcare Conference. It's my pleasure to introduce Prelude Therapeutics, clinical-stage company developing targeted small molecules. Here to present for the company is founder and CEO, Kris Vaddi.
Kris, welcome to the conference, and thank you for joining us. I never know exactly who's in the audience and who might be listening to the webcast, whether they know the company. So if you could, in maybe three to five minutes, can you give us an overview of Prelude before we jump into some questions?
Glad to. And thank you very much for the opportunity to participate in this exciting conference. So as you said, Prelude is a small molecule oncology company. We founded the company in late 2016, really, with the idea of building a strong portfolio of highly differentiated and selective and potent small molecule agents to go after key mechanisms that are driving cancers in patients with highly unmet needs.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |